Analysis and clinical relevance of microparticles from red blood cells

Current Opinion in Hematology

Volumn 17, Issue 6, 2010, Pages 571-577

  Tissot, Jean Daniel ^a   Rubin, Olivier ^a   Canellini, Giorgia ^a  

^a Service Regional Vaudois de Transfusion Sanguine   (Switzerland)

Author keywords

microparticles; proteomics; red blood cells; transfusion

Indexed keywords

ANKYRIN; ERYTHROCYTE ANTIGEN; ERYTHROCYTE BAND 3 PROTEIN; HEMOGLOBIN;

BLOOD GROUP DUFFY SYSTEM; BLOOD GROUP KELL SYSTEM; BLOOD GROUP KIDD SYSTEM; BLOOD GROUP RH; ERYTHROCYTE; ERYTHROCYTE LIFESPAN; ERYTHROCYTE MICROPARTICLE; ERYTHROCYTE PRESERVATION; ERYTHROCYTE TRANSFUSION; HEMATOPOIESIS; HUMAN; HYPERCOAGULABILITY; IMMUNOSUPPRESSIVE TREATMENT; MEMBRANE MICROPARTICLE; MICROCIRCULATION; PRIORITY JOURNAL; PROTEOMICS; REVIEW;

BLOOD PRESERVATION; CELL-DERIVED MICROPARTICLES; ERYTHROCYTE AGING; ERYTHROCYTE TRANSFUSION; ERYTHROCYTES; HUMANS; MICROCIRCULATION;

EID: 78049314080     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32833ec217     Document Type: Review

References (70)

1. Shukla SD, Berriman J, Coleman R, et al. Membrane protein segregation during release of microvesicles from human erythrocytes. FEBS Lett 1978; 90:289-292.
2. Hess C, Sadallah S, Hefti A, et al. Ectosomes released by human neutrophils are specialized functional units. J Immunol 1999; 163:4564-4573.
3. Diamant M,Tushuizen ME, SturkA, Nieuwland R. Cellular microparticles: new players in the field of vascular disease? Eur J Clin Invest 2004; 34:392-401.
4. Simak J, Gelderman MP. Cell membrane microparticles in blood and blood products: potentially pathogenic agents and diagnostic markers. Transfus Med Rev 2006; 20:1-26.
5. Wolf P. The nature and significance of platelet products in human plasma. Br J Haematol 1967; 13:269-288.
6. Greenwalt TJ. The how and why of exocytic vesicles. Transfusion 2006; 46:143-152.
7. Burnier L, Fontana P, Kwak BR, Angelillo-Scherrer A. Cell-derived micro-particles in haemostasis and vascular medicine. Thromb Haemost 2009; 101:439-451.
8. Baj-Krzyworzeka M, Majka M, Pratico D, et al. Platelet-derived microparticles stimulate proliferation, survival, adhesion, and chemotaxis of hematopoietic cells. Exp Hematol 2002; 30:450-459.
9. Piccin A, Murphy WG, Smith OP. Circulating microparticles: pathophysiology and clinical implications. Blood Rev 2007; 21:157-171.
10. VanWijk MJ, VanBavel E, SturkA, Nieuwland R. Microparticles in cardiovascular diseases. Cardiovasc Res 2003; 59:277-287.
11. Aharon A, Brenner B. Microparticles, thrombosis and cancer. Best Pract Res Clin Haematol 2009; 22:61-69.
12. Rubin O, Crettaz D,Tissot JD, Lion N. Microparticles in stored red blood cells: submicron clotting bombs? Blood Transfus 2010; 8 (Suppl 3):s31-s38.
13. Queloz PA, Thadikkaran L, Crettaz D, et al. Proteomics and transfusion medicine: future perspectives. Proteomics 2006; 6:5605-5614.
14. Lion N, Tissot JD. Application of proteomics to hematology: the revolution is starting. Expert Rev Proteomics 2008; 5:375-379.
15. Zolla L. Blood proteomics. Preface. J Proteomics 2010; 73:361-364.
16. Thadikkaran L, Siegenthaler MA, Crettaz D, et al. Recent advances in blood-related proteomics. Proteomics 2005; 5:3019-3034.
17. Rubin O, Crettaz D, Tissot JD, Lion N. Preanalytical and methodological challenges in red blood cell microparticle proteomics. Talanta 2010; 82:1-8.
18. Freyssinet JM, Toti F. Membrane microparticle determination: at least seeing what's being sized! J Thromb Haemost 2010; 8:311-314.
19. An X, Mohandas N. Disorders of red cell membrane. Br J Haematol 2008 141 367-375
20. Zwaal RF, Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 1997; 89:1121-1132.
21. An X, Guo X, Sum H, et al Phosphatidylserine binding sites in erythroid spectrin: location and implications for membrane stability. Biochemistry 2004 43 310-315.
22. Manno S, Takakuwa Y, Mohandas N. Identification of a functional role for lipid asymmetry in biological membranes: phosphatidylserine-skeletal protein interactions modulate membrane stability. Proc Natl Acad Sci USA 2002; 99:1943-1948.
23. Bosman GJ, Werre JM, Willekens FL, Novotny VM. Erythrocyte ageing in vivo and in vitro: structural aspects and implications for transfusion. Transfus Med 2008; 18:335-347.
24. Moskovich O, Fishelson Z. Live cell imaging of outward and inward vesicula-tion induced by the complement c5b-9 complex. J Biol Chem 2007; 282:29977-29986.
25. Werre JM, Willekens FL, Bosch FH, et al. The red cell revisited: matters of life and death. Cell Mol Biol (Noisy-le-grand) 2004; 50:139-145.
26. Willekens FL, Roerdinkholder-Stoelwinder B, Groenen-Dopp YA, et al. Hemoglobin loss from erythrocytes in vivo results from spleen-facilitated vesi-culation. Blood 2003; 101:747-751.
27. Lion N, Crettaz D, Rubin O, Tissot JD. Stored red blood cells: a changing universe waiting for its map(s). J Proteomics 2010; 73:374-385.
28. Lang F, Gulbins E, Lerche H, et al. Eryptosis, a window to systemic disease. Cell Physiol Biochem 2008; 22:373-380.
29. Redding GS, Record DM, Raess BU. Calcium-stressed erythrocyte membrane structure and function for assessing glipizide effects on transglutaminase activation. Proc Soc Exp Biol Med 1991; 196:76-82.
30. Low PS, Willardson BM, Mohandas N, et al. Contribution of the band 3-ankyrin interaction to erythrocyte membrane mechanical stability. Blood 1991; 77:1581-1586.
31. Minetti M, Malorni W. Redox control of red blood cell biology: the red blood cell as a target and source of prooxidant species. Antioxid Redox Signal 2006; 8:1165-1169.
32. Mannu F, Arese P, Cappellini MD, et al. Role of hemichrome binding to erythrocyte membrane in the generation of band-3 alterations in beta-tha-lassemia intermedia erythrocytes. Blood 1995; 86:2014-2020.
33. Kay M. Immunoregulation of cellular life span. Ann N Y Acad Sci 2005; 1057:85-111.
34. Jelezarova E, Lutz HU. IgG naturally occurring antibodies stabilize and promote the generation of the alternative complement pathway C3 conver-tase. Mol Immunol 2005; 42:1393-1403.
35. Arese P, Turrini F, Schwarzer E. Band 3/complement-mediated recognition and removal of normally senescent and pathological human erythrocytes. Cell Physiol Biochem 2005; 16:133-146.
36. Bruce LJ, Beckmann R, Ribeiro ML, et al. A band 3-based macrocomplex of integral and peripheral proteins in the RBC membrane. Blood 2003; 101:4180-4188.
37. Rubin O, Crettaz D, Canellini G, et al. Microparticles in stored red blood cells: an approach using flow cytometry and proteomic tools. Vox Sang 2008; 95:288-297.
38. Bosman GJ, Lasonder E, Groenen-Dopp YA, et al. Comparative proteomics of erythrocyte aging in vivo and in vitro. J Proteomics 2010; 73:396-402.
39. Bosman GJ, Lasonder E, Luten M, et al. The proteome of red cell membranes and vesicles during storage in blood bank conditions. Transfusion 2008; 48:827-835.
40. Willekens FL, Werre JM, Groenen-Dopp YA, et al. Erythrocyte vesiculation: a self-protective mechanism? Br J Haematol 2008; 141:549-556.
41. Salzer U, Zhu R, Luten M, et al. Vesicles generated during storage of red cells are rich in the lipid raft marker stomatin. Transfusion 2008; 48:451-462.
42. Kriebardis AG, Antonelou MH, Stamoulis KE, et al. RBC-derived vesicles during storage: ultrastructure, protein composition, oxidation, and signaling components. Transfusion 2008; 48:1943-1953.
43. Bruckheimer EM, Gillum KD, Schroit AJ. Colocalization of Rh polypeptides and the aminophospholipid transporter in dilauroylphosphatidylcholine-induced erythrocyte vesicles. Biochim Biophys Acta 1995; 1235:147-154.
44. Antonelou MH, Kriebardis AG, Stamoulis KE, et al. Red blood cell aging markers during storage in citrate-phosphate-dextrose-saline-adenine-glu-cose- mannitol. Transfusion 2010; 50:376-389.
45. Card RT. Red cell membrane changes during storage. Transfus Med Rev 1988; 2:40-47.
46. Zubair AC. Clinical impact of blood storage lesions. Am J Hematol 2010; 85:117-122.
47. Karon BS, Hoyer JD, Stubbs JR, Thomas DD. Changes in band 3 oligomeric state precede cell membrane phospholipid loss during blood bank storage of red blood cells. Transfusion 2009; 49:1435-1442.
48. Sparrow RL, Veale MF, Healey G, Payne KA. Red blood cell (RBC) age at collection and storage influences RBC membrane-associated carbohydrates and lectin binding. Transfusion 2007; 47:966-968.
49. Sadallah S, Eken C, Schifferli JA. Erythrocyte-derived ectosomes have im-munosuppressive properties. J Leukoc Biol 2008; 84:1316-1325.
50. Sloand EM, Mainwaring L, Keyvanfar K, et al. Transfer of glycosylphos-phatidylinositol-anchored proteins to deficient cells after erythrocyte transfusion in paroxysmal nocturnal hemoglobinuria. Blood 2004; 104:3782-3788.
51. Simak J, Holada K, Risitano AM, et al. Elevated circulating endothelial membrane microparticles in paroxysmal nocturnal haemoglobinuria. Br J Haematol 2004; 125:804-813.
52. Reid ME, Mohandas N. Red blood cell blood group antigens: structure and function. Semin Hematol 2004; 41:93-117.
53. Pantaleo A, De Franceschi L, Ferru E, et al. Current knowledge about the functional roles of phosphorylative changes of membrane proteins in normal and diseased red cells. J Proteomics 2010; 73:445-455.
54. Cole WF, Rumsby MG, Longster GH, Tovey LA. Changes in the inhibition of specific agglutination by plasma due to microvesicles released from human red cells during storage for transfusion. Vox Sang 1979; 37:73-77.
55. Oreskovic RT, Dumaswala UJ, Greenwalt TJ. Expression of blood group antigens on red cell microvesicles. Transfusion 1992; 32:848-849.
56. Victoria EJ, Branks MJ, Masouredis SP. Immunoreactivity of the Rho(D) antigen in cytoskeleton-free vesicles. Transfusion 1987; 27:32-35.
57. Zimring JC, Hair GA, ChadwickTE, et al. Nonhemolytic antibody-induced loss of erythrocyte surface antigen. Blood 2005; 106:1105-1112.
58. Powers A, Mohammed M, Uhl L, Haspel RL Apparent nonhemolytic alloanti-body-induced red-cell antigen loss from transfused erythrocytes. Blood 2007; 109:4590.
59. Head DJ, Lee ZE, Swallah MM, Avent ND. Ligation of CD47 mediates phosphatidylserine expression on erythrocytes and a concomitant loss of viability in vitro. Br J Haematol 2005; 130:788-790.
60. Lee JS, Gladwin MT. Bad blood: the risks of red cell storage. Nat Med 2010; 16:381-382.
61. Greenwalt TJ, McGuinness CG, Dumaswala UJ. Studies in red blood cell preservation. 4: Plasma vesicle hemoglobin exceeds free hemoglobin. Vox Sang 1991; 61:14-17.
62. Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 2002; 8:1383-1389.
63. Gladwin MT, Kim-Shapiro DB. Storage lesion in banked blood due to hemolysis-dependent disruption of nitric oxide homeostasis. Curr Opin He-matol 2009; 16:515-523.
64. Horne MK, Cullinane AM, Merryman PK, Hoddeson EK. The effect of red blood cells on thrombin generation. Br J Haematol 2006; 133:403-408.
65. Van Beers EJ, Schaap MC, Berckmans RJ, et al. Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease. Haematologica 2009; 94:1513-1519.
66. Westerman M, Pizzey A, Hirschman J, et al. Microvesicles in haemoglobino-pathies offer insights into mechanisms of hypercoagulability, haemolysis and the effects of therapy. Br J Haematol 2008; 142:126-135.
67. Khorana AA, Francis CW, Blumberg N, et al. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med 2008; 168:2377-2381.
68. Liu R, Klich I, RatajczakJ, et al. Erythrocyte-derived microvesicles may transfer phosphatidylserine to the surface of nucleated cells and falsely 'mark'them as apoptotic. Eur J Haematol 2009; 83:220-229.
69. Twomley KM, Rao SV, Becker RC. Proinflammatory, immunomodulating, and prothrombotic properties of anemia and red blood cell transfusions. J Thromb Thrombolysis 2006; 21:167-174.
70. Koch CG, Li L, Sessler DI, et al. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med 2008; 358:1229-1239.